The News

Ablynx announces 2009 full year results

25/02/2010

GHENT, Belgium, 25 February 2010 - Ablynx [Euronext Brussels: ABLX] announced today its consolidated results for 2009, which have been prepared in accordance with IFRS as adopted by the European Union.

2009 Highlights
• €92.3 million in cash, cash equivalents and available-for-sale financial assets and other short term investments at year end
• €21.3 million net cash burn for the year
• 77% increase in revenues to €29.7 million (2008: €16.8 million)
• Initiated a Phase II study in September for its vWF targeting anti-thrombotic, ALX-0081, in a head-to-head comparison with ReoPro® as adjunctive treatment to standard anti-thrombotic therapy in "high risk" patients undergoing a percutaneous coronary intervention (PCI) procedure. Showed proof-of-concept by biomarker for ALX-0081 in December with data from the open label extension of its Phase Ib study
• Reported positive Phase I results for its anti-vWF Nanobody product, ALX-0681, which is being developed in patients with thrombotic thrombocytopenic purpura (TTP)
• Received Orphan Drug Designation from both the FDA and EMEA for its vWF Nanobody programme for the treatment of TTP
• Pfizer successfully completed Phase I trials and initiated Phase II trials for its anti-TNFƒÑ Nanobody product in rheumatoid arthritis (RA) patients in September, which triggered a $4 million milestone payment to Ablynx
• Initiated a Phase I study in December for its RANKL targeting Nanobody, ALX-0141, in healthy postmenopausal women. The drug is being developed initially for the treatment of osteoporosis
• Announced a new pre-clinical development candidate, ALX-0061, a Nanobody  product targeting IL-6R, for the treatment of autoimmune and inflammatory diseases
• Successfully generated functional Nanobodies against GPCRs
• Awarded a total of €1.1 million in grants to further develop new routes of administration for Nanobodies
• Announced important developments in the administration of Nanobody products via pulmonary and needle-free routes together with more data on its  novel proprietary half-life extension technology called NExpedite®
• Received €9 million in milestone payments from Boehringer Ingelheim, as part of its strategic alliance
 
For more information, please contact:

College Hill Life Sciences - for UK/International media enquiries:
Sue Charles, Justine Lamond, Dr John McIntyre
t:   +44 (0)20 7866 7857
e:  ablynx@collegehill.com
 
Ablynx:
Dr. Edwin Moses
Chairman and CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
e:  edwin.moses@ablynx.com
 
Eva-Lotta Allan
Chief Business Officer
t:   +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 / +44 (0)7990 570 900
e:  eva-lotta.allan@ablynx.com

Wim Ottevaere
Chief Financial Officer
t:  +32 (0)9 262 00 11
e: wim.ottevaere@ablynx.com